Anthrax Vaccine Market Size to Hit USD 22.34 Billion by 2035

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Anthrax Vaccine Market

5.1. COVID-19 Landscape: Anthrax Vaccine Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Anthrax Vaccine Market, By Vaccine Platform

8.1. Anthrax Vaccine Market Revenue and Volume Forecast, by Vaccine Platform

8.1.1. Cell-free protective antigen vaccine adsorbed

8.1.1.1. Market Revenue and Volume Forecast

8.1.2. Adjuvanted protective antigen vaccine adsorbed

8.1.2.1. Market Revenue and Volume Forecast

8.1.3. Recombinant protective antigen subunit vaccine

8.1.3.1. Market Revenue and Volume Forecast

8.1.4. Live attenuated spore vaccine for human use

8.1.4.1. Market Revenue and Volume Forecast

8.1.5. Veterinary live spore vaccine

8.1.5.1. Market Revenue and Volume Forecast

Chapter 9. Global Anthrax Vaccine Market, By Indication

9.1. Anthrax Vaccine Market Revenue and Volume Forecast, by Indication

9.1.1. Pre-exposure prophylaxis

9.1.1.1. Market Revenue and Volume Forecast

9.1.2. Post-exposure prophylaxis

9.1.2.1. Market Revenue and Volume Forecast

Chapter 10. Global Anthrax Vaccine Market, By End User

10.1. Anthrax Vaccine Market Revenue and Volume Forecast, by End User

10.1.1. Government stockpiles and public health agencies

10.1.1.1. Market Revenue and Volume Forecast

10.1.2. Military and defense organizations

10.1.2.1. Market Revenue and Volume Forecast

10.1.3. Occupational risk programs (laboratories, first responders, animal handlers)

10.1.3.1. Market Revenue and Volume Forecast

10.1.4. Hospitals and clinics

10.1.4.1. Market Revenue and Volume Forecast

Chapter 11. Global Anthrax Vaccine Market, By Procurement Channel

11.1. Anthrax Vaccine Market Revenue and Volume Forecast, by Procurement Channel

11.1.1. Direct government procurement

11.1.1.1. Market Revenue and Volume Forecast

11.1.2. Defense medical supply procurement

11.1.2.1. Market Revenue and Volume Forecast

11.1.3. Hospital and institutional procurement

11.1.3.1. Market Revenue and Volume Forecast

11.1.4. Specialty distributors

11.1.4.1. Market Revenue and Volume Forecast

Chapter 12. Global Anthrax Vaccine Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Volume Forecast, by Vaccine Platform

12.1.2. Market Revenue and Volume Forecast, by Indication

12.1.3. Market Revenue and Volume Forecast, by End User

12.1.4. Market Revenue and Volume Forecast, by Procurement Channel

12.1.5. U.S.

12.1.5.1. Market Revenue and Volume Forecast, by Vaccine Platform

12.1.5.2. Market Revenue and Volume Forecast, by Indication

12.1.5.3. Market Revenue and Volume Forecast, by End User

12.1.5.4. Market Revenue and Volume Forecast, by Procurement Channel

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Volume Forecast, by Vaccine Platform

12.1.6.2. Market Revenue and Volume Forecast, by Indication

12.1.6.3. Market Revenue and Volume Forecast, by End User

12.1.6.4. Market Revenue and Volume Forecast, by Procurement Channel

12.2. Europe

12.2.1. Market Revenue and Volume Forecast, by Vaccine Platform

12.2.2. Market Revenue and Volume Forecast, by Indication

12.2.3. Market Revenue and Volume Forecast, by End User

12.2.4. Market Revenue and Volume Forecast, by Procurement Channel

12.2.5. UK

12.2.5.1. Market Revenue and Volume Forecast, by Vaccine Platform

12.2.5.2. Market Revenue and Volume Forecast, by Indication

12.2.5.3. Market Revenue and Volume Forecast, by End User

12.2.5.4. Market Revenue and Volume Forecast, by Procurement Channel

12.2.6. Germany

12.2.6.1. Market Revenue and Volume Forecast, by Vaccine Platform

12.2.6.2. Market Revenue and Volume Forecast, by Indication

12.2.6.3. Market Revenue and Volume Forecast, by End User

12.2.6.4. Market Revenue and Volume Forecast, by Procurement Channel

12.2.7. France

12.2.7.1. Market Revenue and Volume Forecast, by Vaccine Platform

12.2.7.2. Market Revenue and Volume Forecast, by Indication

12.2.7.3. Market Revenue and Volume Forecast, by End User

12.2.7.4. Market Revenue and Volume Forecast, by Procurement Channel

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Volume Forecast, by Vaccine Platform

12.2.8.2. Market Revenue and Volume Forecast, by Indication

12.2.8.3. Market Revenue and Volume Forecast, by End User

12.2.8.4. Market Revenue and Volume Forecast, by Procurement Channel

12.3. APAC

12.3.1. Market Revenue and Volume Forecast, by Vaccine Platform

12.3.2. Market Revenue and Volume Forecast, by Indication

12.3.3. Market Revenue and Volume Forecast, by End User

12.3.4. Market Revenue and Volume Forecast, by Procurement Channel

12.3.5. India

12.3.5.1. Market Revenue and Volume Forecast, by Vaccine Platform

12.3.5.2. Market Revenue and Volume Forecast, by Indication

12.3.5.3. Market Revenue and Volume Forecast, by End User

12.3.5.4. Market Revenue and Volume Forecast, by Procurement Channel

12.3.6. China

12.3.6.1. Market Revenue and Volume Forecast, by Vaccine Platform

12.3.6.2. Market Revenue and Volume Forecast, by Indication

12.3.6.3. Market Revenue and Volume Forecast, by End User

12.3.6.4. Market Revenue and Volume Forecast, by Procurement Channel

12.3.7. Japan

12.3.7.1. Market Revenue and Volume Forecast, by Vaccine Platform

12.3.7.2. Market Revenue and Volume Forecast, by Indication

12.3.7.3. Market Revenue and Volume Forecast, by End User

12.3.7.4. Market Revenue and Volume Forecast, by Procurement Channel

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Volume Forecast, by Vaccine Platform

12.3.8.2. Market Revenue and Volume Forecast, by Indication

12.3.8.3. Market Revenue and Volume Forecast, by End User

12.3.8.4. Market Revenue and Volume Forecast, by Procurement Channel

12.4. MEA

12.4.1. Market Revenue and Volume Forecast, by Vaccine Platform

12.4.2. Market Revenue and Volume Forecast, by Indication

12.4.3. Market Revenue and Volume Forecast, by End User

12.4.4. Market Revenue and Volume Forecast, by Procurement Channel

12.4.5. GCC

12.4.5.1. Market Revenue and Volume Forecast, by Vaccine Platform

12.4.5.2. Market Revenue and Volume Forecast, by Indication

12.4.5.3. Market Revenue and Volume Forecast, by End User

12.4.5.4. Market Revenue and Volume Forecast, by Procurement Channel

12.4.6. North Africa

12.4.6.1. Market Revenue and Volume Forecast, by Vaccine Platform

12.4.6.2. Market Revenue and Volume Forecast, by Indication

12.4.6.3. Market Revenue and Volume Forecast, by End User

12.4.6.4. Market Revenue and Volume Forecast, by Procurement Channel

12.4.7. South Africa

12.4.7.1. Market Revenue and Volume Forecast, by Vaccine Platform

12.4.7.2. Market Revenue and Volume Forecast, by Indication

12.4.7.3. Market Revenue and Volume Forecast, by End User

12.4.7.4. Market Revenue and Volume Forecast, by Procurement Channel

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Volume Forecast, by Vaccine Platform

12.4.8.2. Market Revenue and Volume Forecast, by Indication

12.4.8.3. Market Revenue and Volume Forecast, by End User

12.4.8.4. Market Revenue and Volume Forecast, by Procurement Channel

12.5. Latin America

12.5.1. Market Revenue and Volume Forecast, by Vaccine Platform

12.5.2. Market Revenue and Volume Forecast, by Indication

12.5.3. Market Revenue and Volume Forecast, by End User

12.5.4. Market Revenue and Volume Forecast, by Procurement Channel

12.5.5. Brazil

12.5.5.1. Market Revenue and Volume Forecast, by Vaccine Platform

12.5.5.2. Market Revenue and Volume Forecast, by Indication

12.5.5.3. Market Revenue and Volume Forecast, by End User

12.5.5.4. Market Revenue and Volume Forecast, by Procurement Channel

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Volume Forecast, by Vaccine Platform

12.5.6.2. Market Revenue and Volume Forecast, by Indication

12.5.6.3. Market Revenue and Volume Forecast, by End User

12.5.6.4. Market Revenue and Volume Forecast, by Procurement Channel

Chapter 13. Company Profiles

13.1. Emergent BioSolutions

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial PerVaccine Platformance

13.1.4. Recent Initiatives

13.2. GC Biopharma

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial PerVaccine Platformance

13.2.4. Recent Initiatives

13.3. Indian Immunologicals Limited

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial PerVaccine Platformance

13.3.4. Recent Initiatives

13.4. Porton Biopharma

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial PerVaccine Platformance

13.4.4. Recent Initiatives

13.5. Valneva

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial PerVaccine Platformance

13.5.4. Recent Initiatives

13.6. DynPort Vaccine Company

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial PerVaccine Platformance

13.6.4. Recent Initiatives

13.7. Altimmune

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial PerVaccine Platformance

13.7.4. Recent Initiatives

13.8. Colorado Serum Company

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial PerVaccine Platformance

13.8.4. Recent Initiatives

13.9. Merck

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial PerVaccine Platformance

13.9.4. Recent Initiatives

13.10. Bayer

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial PerVaccine Platformance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

Answer : The anthrax vaccine market size is expected to increase from USD 14.18 billion in 2025 to USD 22.34 billion by 2035.

Answer : The anthrax vaccine market is expected to grow at a compound annual growth rate (CAGR) of around 4.65% from 2026 to 2035.

Answer : The major players in the anthrax vaccine market include Emergent BioSolutions, GC Biopharma, Indian Immunologicals Limited, Porton Biopharma, Valneva, DynPort Vaccine Company, Altimmune, Colorado Serum Company, Merck, Bayer, Zoetis, Botswana Vaccine Institute, VECOL S.A., BiogÃ©nesis BagÃ³ and Agrovet Market Animal Health

Answer : The driving factors of the anthrax vaccine market are the increasing government focus on biodefense preparedness and rising investments in biodefense vaccine stockpiling programs.

Answer : North America region will lead the global anthrax vaccine market during the forecast period 2026 to 2035.